<DOC>
	<DOCNO>NCT01964651</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics JNJ-42165279 healthy , young elderly , male female participant repeat oral dose administration .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics JNJ-42165279 Healthy Young Elderly Participants</brief_title>
	<detailed_description>This double-blind ( neither physician participant know treatment participant receives ) , randomize ( study drug assign chance ) , placebo-controlled ( inactive substance compare medication test whether medication real effect clinical study ) trial conduct two part . Thirty two ( 32 ) healthy participant plan included total , four cohort ( group ) . Participants cohort receive JNJ-42165279 ( n=6 ) placebo ( n=2 ) once-daily 10 consecutive day . In Part 1 , two cohort healthy male participant , 18 55 year age , enrol . Cohort A receive 50 mg JNJ-42165279 placebo 10 day , Cohort B receive 30 mg JNJ-42165279 placebo 10 day . In Part 2 , Cohort C consist 8 healthy female participant non-childbearing potential ( surgically sterile postmenopausal ) , 18 58 year age , receive 100 mg JNJ-42165279 placebo 10 day . Cohort D consist 8 healthy elderly male female participant , 65 85 year age , receive 100 mg JNJ-42165279 placebo 10 day . The dose may adapt cohort start base available data . The maximum dose exceed 100 mg once-daily . For participant , study consist eligibility screen examination ( 28 3 day prior first dose administration ) , double-blind treatment phase consist 2 day dose , 10 dosing day ( Day 1 10 ) , 4 day dose ( Day 11 14 ) , follow-up examination ( within 7 14 day last dose administration ) . The total study duration participant exceed 8 week .</detailed_description>
	<criteria>Body Mass Index ( BMI ) 18 30 kg/m2 inclusive Nonsmoker Healthy men 18 55 year , inclusive ( Cohorts A B ) Healthy woman 18 58 year , inclusive ( Cohort C ) Healthy men woman 65 85 year age , inclusive ( Cohort D ) Men sexually active woman childbearing potential vasectomy must agree use barrier method birth control study 3 month receive last dose study drug . In addition , female partner also use appropriate method birth control least duration ( Cohorts A , B , D ) Not childbearing potential due either tubal ligation hysterectomy , postmenopausal ( Cohorts C D ) Clinically significant abnormal value hematology , clinical chemistry urinalysis screen admission Clinically significant abnormal physical examination , vital sign electrocardiogram screen admission History , current , significant medical illness include ( limited ) cardiac disease , hematological disease , lipid abnormality , respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , Parkinson 's disease , infection , illness Investigator considers exclude participant History epilepsy fit unexplained blackout Cohorts A B : contraindication spinal puncture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-42165279</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Elderly</keyword>
	<keyword>Young</keyword>
</DOC>